Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC

Tyrosine kinase inhibitor (TKI) therapy is the recommended first-line treatment for metastatic non-small-cell lung cancer (NSCLC) positive for epidermal growth factor receptor (EGFR) gene mutation. However, most individuals treated with TKI therapy for EGFR-mutant NSCLC will develop tumor resistance...

Full description

Bibliographic Details
Main Authors: Jennifer Novak, Ravi Salgia, Howard West, Miguel A Villalona-Calero, Sagus Sampath, Terence Williams, Victoria Villaflor, Erminia Massarelli, Ranjan Pathak, Marianna Koczywas, Brittney Chau, Arya Amini
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Cancers
Subjects:
lung cancer
epidermal growth factor receptor (EGFR)
EGFR-mutant
non-small cell lung cancer (NSCLC)
stereotactic body radiation therapy (SBRT)
stereotactic radiosurgery (SRS)
Online Access:https://www.mdpi.com/2072-6694/14/16/3983

Internet

https://www.mdpi.com/2072-6694/14/16/3983

Similar Items